







Ε

1800-

1500-

1200-

900-

600-

300-

0

ns

24 h

þg/ml



\*\*\*\*

72 h



ا <sup>25000</sup> ٦

F





TNF



H CCL5/RANTES



Supp. Fig. 1. Mito-transfer alters cytokine production of CD4+ T cells in aged humans. CD4+ T cells from aged humans with or without mito-transfer were stimulated with PMA/Ionomycin. After 24h and 72h stimulation with PMA/Ionomycin, the supernatants were examined by Luminex array for cytokines produced. 9-10 biological replicates per group with  $p \le 0.05 = *$ ,  $p \le 0.01 = **$ , or  $p \le 0.001 = ***$  using paired Student's *t*-test. -O- Elderly CD4<sup>+</sup> T Cells (E-CD4<sup>+</sup> T Cells)





- Elderly CD4<sup>+</sup> T Cells + Mito-Transfer (EM-CD4<sup>+</sup> T Cells)



**Days Post initial stim.** 



## 14

14

**Supp. Fig 2. Impact of mito-transfer on elderly T cell proliferation and viability.** Elderly CD4 T cells with or without mito-transfer were activated via surface cross-linking (CD3/CD28). CD4 T cells either received a single (single) or continuous (cont.) stimulation. **A)** Fold change and **B)** viability of CD4+ T cells with or without mito-transfer after single stimulation. **C)** Fold change and **D)** viability of CD4+ T cells with or without mito-transfer with continuous stimulation. 10 biological replicates per group, with  $p \le 0.05 = *$ ,  $p \le 0.01 = **$ , using paired Student's *t*-test.





50·

**0**.

## **Day 14 - Continuous Stimulation**



Supp Fig 3. Mito-transfer improves T cell activation and reduces human T cell exhaustion and senescence. Donor mitochondria isolated from primary human neonatal dermal fibroblasts were transplanted into CD4+ T cells from elderly humans. Elderly CD4<sup>+</sup> T cells with or without mito-transfer were activated via surface cross-linking (CD3/CD28), T cells either received a single (single) or continuous (cont.) stimulation. The percentages of **A**) CD28- CD27, **B**)  $\beta$ -gal+, **C**) p16+, **D**) Ki67+, and **E**)  $\gamma$ H2A.X+ human CD4+ cells at 7 days after intial activation with CD3/CD28/CD2. The percentages of **F**) CD45RO+ CD62L+, **G**) CD45RO+ CD62L , **H**) CD45RO- CD62L-, **I**) CD45RO- CD62L-, **J**) CD69+, **K**) PD-1+, **L**) PD-1+ LAG3+, **M**) PD-1+ TIM3+, **N**) CD28+, **O**) CD27+, **P**) CD28- CD27 , **Q**) CD57+, **R**) KLRG1+, and **S**)  $\beta$ -Gal+, **T**) p16+, **U**)  $\beta$ -gal+ p16+ human CD4+ T cells at 14 days after continuous stimulation with CD3/CD28/CD2. 10 biological replicates per group, with  $p \le 0.05 = *$ ,  $p \le 0.01 = **$ , using paired Student's t-test.